<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dermatol Ther (Heidelb)</journal-id><journal-id journal-id-type="iso-abbrev">Dermatol Ther (Heidelb)</journal-id><journal-title-group><journal-title>Dermatology and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8210</issn><issn pub-type="epub">2190-9172</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28421455</article-id><article-id pub-id-type="pmc">5453921</article-id><article-id pub-id-type="publisher-id">179</article-id><article-id pub-id-type="doi">10.1007/s13555-017-0179-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Efficacy and Safety of 5-Fluorouracil 0.5%/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Stockfleth</surname><given-names>Eggert</given-names></name><address><email>e.stockfleth@klinikum-bochum.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>von Kiedrowski</surname><given-names>Ralph</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dominicus</surname><given-names>Rolf</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ryan</surname><given-names>John</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ellery</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Falqu&#x000e9;s</surname><given-names>Meritxell</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Ivanoff</surname><given-names>Nathalie</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Azeredo</surname><given-names>Rosario Rodriguez</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0490 981X</institution-id><institution-id institution-id-type="GRID">grid.5570.7</institution-id><institution>Department of Dermatology, </institution><institution>Ruhr-University, </institution></institution-wrap>Bochum, Germany </aff><aff id="Aff2"><label>2</label>Dermatological Practice, Selters, Germany </aff><aff id="Aff3"><label>3</label>Proderma, D&#x000fc;lmen, Germany </aff><aff id="Aff4"><label>4</label>The Alverton Practice, Penzance, UK </aff><aff id="Aff5"><label>5</label>Cape Cornwall Surgery, Penzance, UK </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.474012.4</institution-id><institution/><institution>Almirall S.A., </institution></institution-wrap>Barcelona, Spain </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2017</year></pub-date><volume>7</volume><issue>2</issue><fpage>263</fpage><lpage>263</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d29e91" ext-link-type="doi" xlink:href="10.1007/s13555-016-0161-2"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Dermatol Ther (Heidelb) (2017) 7:81&#x02013;96 DOI 10.1007/s13555-016-0161-2</title><p>The authors would like to publish an erratum to correct the mistakes in Fig.&#x000a0;4 legend and in the text under the heading &#x0201c;Study Assessments and Endpoints&#x0201d; in the published article. The correct texts are given below.<list list-type="order"><list-item><p>Under the Fig.&#x000a0;4 legend the text currently reads: &#x0201c;a Partial clearance defined as &#x02264;75% reduction in the number of clinically visible AK lesions. 5-FU/SA 5-fluorouracil 0.5%/salicylic acid 10%, AK actinic keratosis&#x0201d;.</p><p>The figure &#x0201c;&#x02264;75%&#x0201d; should be &#x0201c;&#x02265;75%&#x0201d;.</p></list-item><list-item><p>The first paragraph of &#x0201c;Study Assessments and Endpoints&#x0201d; has repeated text. The text &#x0201c;and proportional change from baseline in the total number of lesions at each treatment visit and 8&#x000a0;weeks after the end of treatment.&#x0201d; should be removed.
</p></list-item></list>
</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s13555-016-0161-2.</p></fn></fn-group><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</p></ack></back></article>